350 related articles for article (PubMed ID: 16633991)
21. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function.
Saelen MG; Prøsch LK; Gudmundsdottir H; Dyrbekk D; Helge Hunderi O; Arnesen E; Paulsen D; Skjønsberg H; Os I
Blood Press; 2005; 14(3):170-6. PubMed ID: 16036497
[TBL] [Abstract][Full Text] [Related]
22. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
23. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
24. Managing hypertension using combination therapy.
Frank J
Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
[TBL] [Abstract][Full Text] [Related]
25. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
Tocci G; Sciarretta S; Facciolo C; Volpe M
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
[TBL] [Abstract][Full Text] [Related]
27. Clinical overview of antihypertensive classes--clinically relevant differences: myths or facts? Based on a presentation by Alan H. Gradman, MD.
Am J Manag Care; 2000 Mar; 6(4 Suppl):S197-210. PubMed ID: 10977460
[TBL] [Abstract][Full Text] [Related]
28. ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
Ruilope LM; Segura J; Schiffrin EL
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):74-9. PubMed ID: 12806588
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of antihypertensive treatment in chronic renal failure: to what extent and with which drugs do patients treated by nephrologists achieve the recommended blood pressure?
Giverhaug T; Falck A; Eriksen BO
J Hum Hypertens; 2004 Sep; 18(9):649-54. PubMed ID: 15002005
[TBL] [Abstract][Full Text] [Related]
30. Antihypertensive therapy in the presence of proteinuria.
Sarafidis PA; Khosla N; Bakris GL
Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
[TBL] [Abstract][Full Text] [Related]
31. [Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension].
Stern N; Grossman E; ; ; ;
Harefuah; 2003 Apr; 142(4):309-11, 315. PubMed ID: 12754885
[TBL] [Abstract][Full Text] [Related]
32. Treatment selection considerations for the hypertensive diabetic patient.
Christlieb AR
Arch Intern Med; 1990 Jun; 150(6):1167-74. PubMed ID: 2191633
[TBL] [Abstract][Full Text] [Related]
33. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
Ruggenenti P; Perna A; Ganeva M; Ene-Iordache B; Remuzzi G;
J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240
[TBL] [Abstract][Full Text] [Related]
34. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
35. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Lebel M; Rodrigue ME; Agharazii M; Larivière R
Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic management of hypertension in patients with diabetes.
Whalen KL; Stewart RD
Am Fam Physician; 2008 Dec; 78(11):1277-82. PubMed ID: 19069021
[TBL] [Abstract][Full Text] [Related]
37. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
Boucek P
Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacological hypertension therapy].
Pedersen OL; Christensen KL; Bang LE; Ibsen H; Schultz-Larsen P
Ugeskr Laeger; 2009 Jun; 171(24):2022-5. PubMed ID: 19523367
[TBL] [Abstract][Full Text] [Related]
39. The metabolic syndrome in hypertension: European society of hypertension position statement.
Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
[TBL] [Abstract][Full Text] [Related]
40. Renal protection in hypertensive patients: selection of antihypertensive therapy.
Wenzel RR
Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
